

# Controlled enzymatic production of astrocytic hydrogen peroxide protects neurons from oxidative stress via an Nrf2-independent pathway

Renée E. Haskew-Layton<sup>a,1</sup>, Jimmy B. Payappilly<sup>a</sup>, Natalya A. Smirnova<sup>a</sup>, Thong C. Ma<sup>a</sup>, Kelvin K. Chan<sup>a</sup>, Timothy H. Murphy<sup>b</sup>, Hengchang Guo<sup>a</sup>, Brett Langley<sup>a</sup>, Rukhsana Sultana<sup>c</sup>, D. Allan Butterfield<sup>c</sup>, Sandro Santagata<sup>d,e</sup>, Melissa J. Alldred<sup>f</sup>, Irina G. Gazaryan<sup>a</sup>, George W. Bell<sup>d</sup>, Stephen D. Ginsberg<sup>f</sup>, and Rajiv R. Ratan<sup>a,1</sup>

<sup>a</sup>The Burke Medical Research Institute, Department of Neurology and Neuroscience, Weill Medical College of Cornell University, White Plains, NY 10605; <sup>b</sup>Kinsmen Laboratory of Neurological Research, Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada V6T 1Z3; <sup>c</sup>Department of Chemistry, Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40536; <sup>d</sup>The Whitehead Institute for Biomedical Research, Cambridge, MA 02142; <sup>e</sup>Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115; and <sup>f</sup>Center for Dementia Research, Nathan Kline Institute and the New York University Langone Medical Center, Orangeburg, NY 10962

Edited by Solomon H. Snyder, The Johns Hopkins University School of Medicine, Baltimore, MD, and approved August 24, 2010 (received for review March 26, 2010)

Neurons rely on their metabolic coupling with astrocytes to combat oxidative stress. The transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) appears important for astrocyte-dependent neuroprotection from oxidative insults. Indeed, Nrf2 activators are effective in stroke, Parkinson disease, and Huntington disease models. However, key endogenous signals that initiate adaptive neuroprotective cascades in astrocytes, including activation of Nrf2-mediated gene expression, remain unclear. Hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) plays an important role in cell signaling and is an attractive candidate mediator of adaptive responses in astrocytes. Here we determine (i) the significance of H<sub>2</sub>O<sub>2</sub> in promoting astrocyte-dependent neuroprotection from oxidative stress, and (ii) the relevance of H<sub>2</sub>O<sub>2</sub> in inducing astrocytic Nrf2 activation. To control the duration and level of cytoplasmic H<sub>2</sub>O<sub>2</sub> production in astrocytes cocultured with neurons, we heterologously expressed the H<sub>2</sub>O<sub>2</sub>-producing enzyme *Rhodotorula gracilis* D-amino acid oxidase (rgDAAO) selectively in astrocytes. Exposure of rgDAAO-astrocytes to D-alanine lead to the concentration-dependent generation of H<sub>2</sub>O<sub>2</sub>. Seven hours of low-level H<sub>2</sub>O<sub>2</sub> production (~3.7 nmol·min<sup>-1</sup>·mg protein) in astrocytes protected neurons from oxidative stress, but higher levels (~130 nmol·min<sup>-1</sup>·mg protein) were neurotoxic. Neuroprotection occurred without direct neuronal exposure to astrocyte-derived H<sub>2</sub>O<sub>2</sub>, suggesting a mechanism specific to astrocytic intracellular signaling. Nrf2 activation mimicked the effect of astrocytic H<sub>2</sub>O<sub>2</sub> yet H<sub>2</sub>O<sub>2</sub>-induced protection was independent of Nrf2. Astrocytic protein tyrosine phosphatase inhibition also protected neurons from oxidative death, representing a plausible mechanism for H<sub>2</sub>O<sub>2</sub>-induced neuroprotection. These findings demonstrate the utility of rgDAAO for spatially and temporally controlling intracellular H<sub>2</sub>O<sub>2</sub> concentrations to uncover unique astrocyte-dependent neuroprotective mechanisms.

Reactive oxygen species (ROS), such as hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), are products of cellular respiration and enzymatic activity (1). H<sub>2</sub>O<sub>2</sub> acts as a second messenger molecule by inhibiting protein tyrosine phosphatases (PTPs), activating kinases (i.e., MAP kinases), and by inducing transcription factor activation (i.e., NFκB, FOXO, and p53) (2–6). Not surprisingly, H<sub>2</sub>O<sub>2</sub> plays an integral role in diverse biological processes, such as chemotaxis, apoptosis, axon repulsion, and neurotransmitter regulation (3, 6–9). However, ROS accumulation beyond a homeostatic set point can lead to the net oxidation of cellular constituents leading to cell dysfunction or death, termed oxidative stress. The CNS is particularly susceptible to oxidative stress and thus oxidative damage is a characteristic of almost all acute and neurodegenerative disorders, including Alzheimer's disease, Parkinson disease, stroke, and traumatic brain and spinal cord injury (10). However, because neurons have limited

antioxidant capacity, they rely heavily on their metabolic coupling with astrocytes to combat oxidative stress (11).

In the CNS the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) plays an integral role in astrocyte-mediated protection of neurons from oxidative stress. Nrf2 facilitates the transcription of antioxidant genes containing the antioxidant response element (ARE) in their promoters (12). Examples of ARE-containing genes include heme oxygenase 1 (*HO-1*), NADPH-quinone oxidoreductase (*NOQ1*), and those involved in glutathione (GSH) biosynthesis, use, and export (i.e., GSH synthase, glutathione S-transferase, and multidrug resistance protein 1) (11). Indeed, Nrf2-mediated GSH biosynthesis and release from astrocytes protects neurons from oxidative stress (11), and Nrf2 overexpression specifically in astrocytes leads to neuroprotection in in vivo models, such as Parkinson disease and amyotrophic lateral sclerosis (ALS) (13, 14).

Thus, the established role that astrocytic-Nrf2 plays in ameliorating CNS disease models has prompted intense interest in identifying endogenous signals that trigger astrocytic Nrf2 activation. Electrophilic agents have been extensively characterized as Nrf2 activators via their ability to disrupt Keap1 (Kelch-like ECH-associated protein 1)-facilitated Nrf2 proteasomal degradation by targeting critical Keap1 cysteine residues (15). However, whether ROS, such as H<sub>2</sub>O<sub>2</sub>, also represent key agents capable of stabilizing Nrf2 remains a matter of controversy. Several lines of evidence show that exogenous H<sub>2</sub>O<sub>2</sub> or enzymatic models of extracellular H<sub>2</sub>O<sub>2</sub> production promote Nrf2 activation; yet other studies have found either no effect or a limited effect of H<sub>2</sub>O<sub>2</sub> on Nrf2 activation, requiring high concentrations to promote Nrf2 activation (16–19).

In the present study we have developed a system that allows for the precise spatial, temporal, and quantitative control of astrocytic H<sub>2</sub>O<sub>2</sub> in an astrocyte-neuron coculture model. Our results show that low-level astrocyte-derived H<sub>2</sub>O<sub>2</sub> confers neuroprotection from GSH depletion-induced oxidative stress independent of Nrf2 activation.

Author contributions: R.E.H.-L., J.B.P., N.A.S., H.G., B.L., S.S., M.J.A., I.G.G., S.D.G., and R.R.R. designed research; R.E.H.-L., J.B.P., N.A.S., T.C.M., K.K.C., H.G., B.L., S.S., and M.J.A. performed research; R.E.H.-L., N.A.S., T.C.M., T.H.M., B.L., R.S., D.A.B., I.G.G., and R.R.R. contributed new reagents/analytic tools; R.E.H.-L., T.C.M., K.K.C., S.S., G.W.B., S.D.G., and R.R.R. analyzed data; and R.E.H.-L., J.B.P., I.G.G., and R.R.R. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

Freely available online through the PNAS open access option.


<sup>1</sup>To whom correspondence may be addressed. E-mail: rrr2001@med.cornell.edu or rhaskew@burke.org.

This article contains supporting information online at [www.pnas.org/lookup/suppl/doi:10.1073/pnas.1003996107/-DCSupplemental](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1003996107/-DCSupplemental).

## Results

**Temporal and Quantitative Regulation of Astrocytic H<sub>2</sub>O<sub>2</sub> Production via *Rhodotorula gracilis* D-Amino Acid Oxidase.** D-amino acid oxidase (DAAO) is a peroxisomal flavoenzyme that oxidatively deaminates D-amino acids into their corresponding imino acids, producing H<sub>2</sub>O<sub>2</sub> as a byproduct (20, 21) (Fig. 1A). In contrast to other enzymatic models of H<sub>2</sub>O<sub>2</sub> production, such as glucose oxidase, monoamine oxidase, or superoxide dismutase, DAAO permits precise H<sub>2</sub>O<sub>2</sub> production via the manipulation of substrate (D-amino acids) availability, which are generally scarce in mammalian cells. We constructed adenoviruses containing flag-tagged cDNA for *Rhodotorula gracilis* (red yeast) DAAO (rgDAAO) lacking its peroxisomal targeting sequence, which directs rgDAAO expression to the cytoplasm and thus circumvents the avid scavenging of H<sub>2</sub>O<sub>2</sub> in peroxisomes by catalase (21). We selected rgDAAO as a H<sub>2</sub>O<sub>2</sub> source because it has higher catalytic activity and is less prone to auto-oxidation-induced inactivation than mammalian DAAO (20).

Cytoplasmic rgDAAO staining (via its flag epitope) was observed in ~80% of primary rat astrocytes transduced with rgDAAO adenoviruses (adDAAO), but was not detectable in empty vector transduced (adEV) astrocytes (Fig. 1B). As expected, the addition of the rgDAAO substrate D-alanine (2 mM, D-Ala) to the bathing media stimulated H<sub>2</sub>O<sub>2</sub> production in adDAAO astrocytes (Fig. 1C). Because D-Ala alone was not sufficient to maintain continuous H<sub>2</sub>O<sub>2</sub> production beyond 10 min, the bathing media was further supplemented with the DAAO cofactor flavin adenine dinucleotide (FAD) at a range from 0.08 μM to 5 μM (Fig. 1C). It was found that 2.5 μM FAD was required for sustained H<sub>2</sub>O<sub>2</sub> production in the presence of D-Ala (Fig. 1C), and thus for subsequent experiments D-Ala treatments were supplemented with 2.5 μM FAD. In the absence of D-Ala, rgDAAO expression did not evoke H<sub>2</sub>O<sub>2</sub> production but adding 0.016 to 4 mM D-Ala to the media led to a concentration-dependent increase in the rate of H<sub>2</sub>O<sub>2</sub> production (Fig. 1D). We did not detect any increases in H<sub>2</sub>O<sub>2</sub> production from




**Fig. 1.** Heterologous expression of rgDAAO as a tool for regulating intracellular H<sub>2</sub>O<sub>2</sub> production in astrocytes. (A) Schematic representation of the oxidative deamination of D-amino acids into imino acids by DAAO. As O<sub>2</sub> is used to recycle reduced FAD back to oxidized FAD, H<sub>2</sub>O<sub>2</sub> is produced as a byproduct. Ammonia (NH<sub>4</sub><sup>+</sup>) is also produced as a byproduct following the conversion of imino acids to α-keto acids. (B) Astrocytes were transduced with adEV or adDAAO for 4 d. Nuclear DAPI staining is blue; anti-flag (rgDAAO) is red. (Scale bar, 50 μm.) Images are representative of four independent experiments. (C) AdDAAO transduced astrocytes were treated with 2 mM D-Ala + 2.5 μM FAD and, ~30 s later, extracellular H<sub>2</sub>O<sub>2</sub> levels were measured. Values represent optical density units averaged from five experiments ± SEM. (D) Control (nontransduced), adEV, or adDAAO astrocytes were treated with D-Ala + 2.5 μM FAD and ~30 s later continuous H<sub>2</sub>O<sub>2</sub> production was measured for 1 h. The control values (black symbols) are obscured by the adEV values (blue symbols). Data are the means of the rate of H<sub>2</sub>O<sub>2</sub> production for five experiments ± SEM. \*\*\*, *P* ≤ 0.001, adDAAO vs. CT and adEV. (Inset) A reduced scale of data within the hatched box.

control (nontransduced) or adEV-astrocytes with the addition of FAD or any of the D-Ala concentrations tested (Fig. 1D). Thus, H<sub>2</sub>O<sub>2</sub> production in cells expressing rgDAAO can be manipulated in a concentration dependent manner by the addition of varying concentrations of D-Ala.

**GSH Depletion-Induced Oxidative Stress in Astrocyte-Neuron Cocultures.** Glutamate or its analogs (i.e., homocysteic acid, HCA) induce the neurotoxicity of immature neurons independent of NMDA receptor-mediated excitotoxicity (Fig. S1A–C) (22). Rather, glutamate inhibits cystine transport and thus leads to the subsequent loss of intracellular cysteine and depletion of the antioxidant GSH, culminating in oxidative stress (22). We sought to define experimental conditions in which the oxidative glutamate toxicity of neurons could be studied using a physiologically relevant ratio of astrocytes to neurons. Thus, primary rat neurons (1 day in vitro, DIV) were plated on top of a confluent monolayer of astrocytes (14–21 DIV) with 5 mM HCA in the bathing medium. Astrocyte-neuron cocultures exposed to 1.25 through 20 mM HCA for 24 h (time when no cell death is observed) showed a concentration-dependent decrease in intracellular GSH levels (Fig. 2A). As expected, exposure to ≥5 mM HCA for 48 h resulted in significant neuronal death (Fig. 2B and Fig. S1D) but no astrocytic death (Fig. 2B and Fig. S1E). To verify a specific effect of GSH depletion in mediating the neuronal death, the bathing media was supplemented with cystine (to overcome competitive inhibition of cystine transport by HCA) and *N*-acetylcysteine (NAC, an antioxidant that supports GSH synthesis by delivering cysteine independent of the X<sub>c</sub><sup>-</sup> transporter), both of which partially blocked HCA-induced GSH depletion (Fig. S1F). To verify that the neurons ultimately die because of oxidative stress, vitamin E [a lipophilic antioxidant incapable of preventing GSH-depletion (Fig. S1F)] was added to the cocultures. All of these conditions abrogated HCA-induced neuronal death (Fig. 2C). These studies establish astrocyte-neuron coculture conditions under which neurons can be selectively killed by HCA in the presence of confluent astrocytes.

**Astrocytic H<sub>2</sub>O<sub>2</sub> Production Evokes Resistant of Neurons to Oxidative Stress.** We next sought to identify kinetic parameters of H<sub>2</sub>O<sub>2</sub> production in astrocytes capable of protecting neurons from oxidative stress. To determine the amplitude and duration of astrocytic H<sub>2</sub>O<sub>2</sub> production necessary to modulate oxidative




**Fig. 2.** Glutathione depletion in an astrocyte-neuron coculture model induces neuronal death via oxidative stress. (A) Astrocyte-neuron cocultures were treated ± HCA for 24 h. \*\*\**P* ≤ 0.001, HCA concentrations vs. control (astrocytes). \*\**P* ≤ 0.01 HCA concentrations vs. control (neurons). (B) Astrocyte-neuron cocultures were treated ± HCA for 48 h. Representative phase-contrast images of live cells from four independent experiments show neurons plated ± HCA on astrocytes (Upper). Representative images from four experiments show the astrocyte specific marker GFAP (red), the neuron specific marker MAP2 (green), and the nuclear marker DAPI (blue). (Scale bars, 50 μm.) (C) Neurons were plated ± HCA coapplied with 300 μM L-cystine, 100 μM NAC, or 100 μM vitamin E (α-tocopherol) on astrocytes for 48 h. \*\**P* ≤ 0.01, HCA alone vs. all other groups. Values are the averages of four to five experiments ± SEM for all data within the figure.

neuronal death, we cocultured neurons with adDAAO astrocytes and bathed the cocultures with D-Ala (Fig. 3A). Low-level H<sub>2</sub>O<sub>2</sub> production induced by 0.016 mM D-Ala (~3.7 nmol-min-mg protein) (Fig. 1D) over 7 h protected the neurons from HCA (Fig. 3B). Although low-level H<sub>2</sub>O<sub>2</sub> production in adDAAO astrocytes did not affect neuronal viability in the absence of HCA, higher levels of H<sub>2</sub>O<sub>2</sub> produced in astrocytes (~133 nmol-min-mg protein) killed neighboring neurons, even without HCA present (Fig. 3B). D-Ala treatment in control or adEV astrocytes had no effect on neuronal viability (Fig. 3C), and all of the conditions tested did not alter neuronal adherence to the astrocytes (Fig. S24).


We next used 10 U/mL of the H<sub>2</sub>O<sub>2</sub> scavenging-enzyme catalase (CAT), added to the bathing media, to abrogate extracellular adDAAO-generated H<sub>2</sub>O<sub>2</sub> released from the astrocytes (Fig. 3D). Indeed, the extracellular catalase prevented neuronal death caused by 2 mM D-Ala-induced H<sub>2</sub>O<sub>2</sub> production in the absence of HCA (Fig. 3E). However, the protective effect of low-level astrocytic H<sub>2</sub>O<sub>2</sub> production (0.016 mM D-Ala) was not altered by scavenging extracellular H<sub>2</sub>O<sub>2</sub> with catalase in HCA-treated cultures (Fig. 3E). These data suggest that high-level H<sub>2</sub>O<sub>2</sub> production from astrocytes diffuses out of the cells to exert a neurotoxic effect. In contrast, the neuroprotective effect of low-level astrocytic H<sub>2</sub>O<sub>2</sub> production is likely astrocyte-specific. Of note, forced expression of rgDAAO in astrocytes was sufficient to protect mature neurons (14 DIV) from NMDA-induced toxicity independent of D-Ala exposure (Fig. S2 B and C). Such an effect may be the result of long-term endogenous D-serine

metabolism by rgDAAO, yielding increased H<sub>2</sub>O<sub>2</sub> generation in astrocytes or diminished D-serine (an NMDA coagonist) levels in synaptically active neurons.

To evaluate if DAAO/D-Ala-generated H<sub>2</sub>O<sub>2</sub> is working via an intracellular astrocyte-specific mechanism to protect immature neurons, we generated H<sub>2</sub>O<sub>2</sub> for 4, 7, or 24 h in adDAAO astrocytes in the absence of neurons (Fig. 4A). We removed the D-Ala from the medium, washed to remove residual H<sub>2</sub>O<sub>2</sub> production (Fig. S34), and added neurons (plus HCA to induce oxidative stress) to the H<sub>2</sub>O<sub>2</sub> "primed" astrocytes. Despite never having "seen" H<sub>2</sub>O<sub>2</sub>, the neurons plated with adDAAO astrocytes (primed for 7 h with 0.016 mM D-Ala to induce low-level H<sub>2</sub>O<sub>2</sub> production) were resistant to GSH depletion-induced death (Fig. 4B and C). The neuroprotective effect was diminished at 24 h and completely absent at 4 h preconditioning (Fig. 4C). There was also a lack of neuroprotection at all time points by high H<sub>2</sub>O<sub>2</sub> levels (Fig. 4C) (0.25 and 2 mM D-Ala) that was not a result of astrocyte toxicity (Fig. S3B). Indeed, D-Ala treatment in control or adEV astrocytes had no effect on neuronal viability (Fig. 4D) and all of the conditions tested did not alter neuronal adherence to the astrocytes (Fig. S3C). These studies establish the amplitude and duration-dependence required for astrocytic H<sub>2</sub>O<sub>2</sub>'s effect on neuronal protection, suggesting that a low level of sustained H<sub>2</sub>O<sub>2</sub>



**Fig. 3.** DAAO-induced astrocytic H<sub>2</sub>O<sub>2</sub> production confers resistance of adjacent neurons from oxidative stress. (A) Schematic representation of experimental design. (B) Neurons were plated ± D-Ala + 2.5 μM FAD on adDAAO astrocytes for 7 h followed by wash-off and 48 h HCA treatment. \*,  $P \leq 0.05$ , 0.016 mM D-Ala vs. HCA control; \*\*,  $P \leq 0.01$ , 2 mM D-Ala vs. all other groups within 0 mM HCA group. (C) Neurons were plated ± D-Ala + 2.5 μM FAD on control or adEV astrocytes for 7 h followed by 48-h HCA treatment. (D) AdDAAO astrocytes were treated with ± D-Ala + 2.5 μM FAD in the presence or absence of extracellular catalase (CAT) for 30 min. The media was removed after 30 min and extracellular H<sub>2</sub>O<sub>2</sub> measured. (Inset) Reduced scale, for clarity, of low level H<sub>2</sub>O<sub>2</sub> production. \*\*\*,  $P < 0.001$ , 0 U/mL CAT vs. 10 U/mL CAT. (E) Neurons were plated with D-Ala + 2.5 μM FAD + extracellular CAT on adDAAO astrocytes for 7 h followed by wash-off and 48 h ± HCA treatment. \*,  $P \leq 0.05$ , 0.016 mM D-Ala vs. FAD + HCA control. Values are the averages of four to five experiments ± SEM for all data within figure.




**Fig. 4.** Low-level H<sub>2</sub>O<sub>2</sub> confers neuroprotection via an astrocyte-specific mechanism. (A) Schematic representation of experimental design. (B) AdDAAO astrocytes were pretreated with ± D-Ala + 2.5 μM FAD for 7 h. Following D-Ala wash-off, neurons were plated ± HCA and phase-contrast images of live cells taken 48 h later, representative of three independent experiments. (Scale bar, 50 μm.) (C) AdDAAO astrocytes were pretreated ± D-Ala + 2.5 μM FAD for 4, 7, or 24 h. Following D-Ala wash-off, neurons were plated ± 5 mM HCA on the astrocytes for 48 h. (E) AdDAAO, adDAAO + adCAT, or adCAT astrocytes were pretreated ± 0.016 mM D-Ala + 2.5 μM FAD for 7 h. Following D-Ala wash-off, neurons were plated with 5 mM HCA for 48 h. \*,  $P \leq 0.05$ , adDAAO + 0.016 mM D-Ala vs. adDAAO control. Values are the averages of four to five experiments ± SEM for all data within the figure.

production for 7 h (not 4 or 24 h) induces an optimal “state change” in astrocytes that renders them capable of protecting neurons from oxidative death.

To verify that the metabolism of D-Ala by DAAO imparts its effects on astrocytes via  $H_2O_2$ , we coexpressed CAT, using an adenoviral vector (adCAT), with adDAAO specifically in astrocytes to scavenge intracellular  $H_2O_2$  production only in astrocytes. Immunoblotting verified increased CAT expression in adCAT-astrocytes and showed that this increased expression persisted in the presence of rgDAAO (Fig. S3D), and the cotransduction of adCAT did not interfere with rgDAAO expression (Fig. S3E). AdDAAO-astrocytes cotransduced with adCAT attenuated  $H_2O_2$  production (Fig. S3F), and this reduction in  $H_2O_2$  by adCAT abrogated the neuroprotective effect of D-Ala in adDAAO astrocytes (Fig. 4E). These results, along with our inability to measure a change in the DAAO-byproduct ammonia at the neuroprotective concentration of D-Ala (0.016 mM D-Ala) (Fig. S3G), support a critical role of  $H_2O_2$  in mediating the astrocyte-dependent neuroprotection.

**Nrf2 Activation in Astrocytes Induces Neuroprotection.** Prior studies have suggested that  $H_2O_2$  can activate Nrf2 in astrocytes (18). We therefore examined whether Nrf2, which stimulates the transcription of antioxidant genes and has been implicated in astrocyte-dependent neuroprotection (11, 14), is necessary for the neuroprotective effect of astrocytic  $H_2O_2$ . As a positive control for these studies we pretreated astrocytes, before neuronal plating, with the small molecule electrophilic Nrf2 activators sulforaphane (SF), tert-butylhydroquinone (tBHQ) and 15-deoxy- $\Delta$ 12,14-prostaglandin J2 (15d-PGJ2), or overexpressed Nrf2 using an adenoviral vector. As expected, the electrophiles and Nrf2 overexpression mimicked the neuroprotective effect seen with astrocytic  $H_2O_2$  (Fig. S4A and B). To verify that the Nrf2 activators induce transcription via the ARE, the binding site for Nrf2, we constructed adenoviruses that express the ARE promoter sequence upstream of a luciferase reporter (ARE-Luc). Indeed, SF activated the ARE in astrocytes (Fig. S4C). To verify that astrocytic Nrf2 is required for the neuroprotection observed with SF, we treated astrocytes with siRNAs targeted against Nrf2 (which decreased Nrf2 protein levels and mRNA levels by 50 to 60%, and abrogated both SF-induced ARE-Luc activity and SF-induced protein levels of HO-1 (a downstream target of Nrf2) (Fig. S4D–G). Thus, as expected, Nrf2-siRNA blocked the SF-induced astrocytic neuroprotection (Fig. S4H) (which was not a result of siRNA-induced toxicity) (Fig. S4I and J). In addition, overexpression of the Nrf2 repressor Keap1 abrogated the astrocyte-dependent SF-mediated neuroprotection (Fig. S4K).

**Astrocytic  $H_2O_2$  Induces Neuroprotection Independent of Nrf2.** With confirmation in hand that Nrf2 is necessary for astrocyte-mediated electrophilic neuroprotection, we next asked whether Nrf2 is also necessary for  $H_2O_2$ -induced neuroprotection. Surprisingly, the Nrf2-siRNAs failed to block the neuroprotective effect of adDAAO-mediated astrocytic  $H_2O_2$  production (Fig. 5A). Despite higher levels of neuronal death in cultures exposed to both transfection reagent and HCA, the fold-protection induced by DAAO plus D-Ala treatment in the presence of transfection reagent and Nrf2-siRNAs remained consistent with the previously observed protection (compare Fig. 4C with Fig. 5A). We believe it unlikely that the persistent neuroprotection reflects the incomplete knock-down of Nrf2, because adDAAO-induced  $H_2O_2$  production failed to augment markers of Nrf2 activation, such as HO-1 protein levels (Fig. 5B) and ARE-Luc activity (Fig. 5C). We also confirmed that the lack of effect of adDAAO-mediated  $H_2O_2$  production on ARE-Luc activity was not a result of diminished rgDAAO expression (Fig. S5A), diminished adARE-Luc transduction (Fig. S5B), or a lack of  $H_2O_2$  production (Fig. S5C) in astrocytes cotransduced with adDAAO and adARE-Luc. We also confirmed that exogenous treatment of astrocytes with  $H_2O_2$  (up to 30  $\mu$ M  $H_2O_2$ ) failed to initiate significant ARE-Luc activity (Fig. 5D). We were unable



**Fig. 5.** Low-level, intracellular  $H_2O_2$  generated via heterologous DAAO expression in astrocytes confers neuroprotection independent of Nrf2. (A) AdDAAO-transduced astrocytes were transfected with vehicle (Tsox-CT) or siRNAs (siScrm1 or siNrf2-1, -2, or -3) and treated for 7 h with 0.016 mM D-Ala. Following wash-off, neurons were plated with 5 mM HCA for 48 h. \*,  $P \leq 0.05$ , Tsox-CT, siScrm1, siNrf2-1 and -3 vs. HCA; \*\*,  $P \leq 0.01$  siNrf2-2 vs. HCA. (B) Immunoblot of nontransduced (CT) astrocytes  $\pm$  5  $\mu$ M SF (24 h) or adDAAO-transduced astrocytes  $\pm$  D-Ala + 2.5  $\mu$ M FAD (7 h). The last lane is recombinant HO-1 protein. The blot is representative of three independent experiments. (C) AdDAAO + adARE-Luc astrocytes were treated with 5  $\mu$ M SF for 24 h or D-Ala for 7 h. \*\*\*,  $P \leq 0.001$ , SF vs. control. (D) adARE-Luc or mARE-Luc astrocytes were treated with 5  $\mu$ M SF or  $H_2O_2$  for 7 h. \*,  $P \leq 0.05$ , SF vs. control ARE-Luc. Values are the averages of three to five experiments  $\pm$  SEM for all data within the figure.

to test higher levels of exogenous  $H_2O_2$  on ARE-Luc activity because of astrocyte toxicity (Fig. S5D). Finally, the Nrf2 electrophilic activators SF or tBHQ maintain their astrocytic protective effect even with overexpression of the  $H_2O_2$  scavenging enzyme CAT, further supporting disparate mechanisms of the electrophile and  $H_2O_2$  protective pathways (Fig. S5E).

Because Nrf2-dependent neuroprotection correlates strongly with enhanced astrocytic GSH release (11), we examined if the astrocyte-dependent neuroprotective effect could be sustained with astrocyte conditioned media, and if astrocytic GSH levels increase in response to adDAAO-generated  $H_2O_2$ . Consistent with a lack of Nrf2 involvement in the  $H_2O_2$  effect, conditioned media from SF-treated astrocytes protected the neurons from oxidative stress, but the media from  $H_2O_2$ -primed astrocytes failed to induce neuroprotection (Fig. S6A). In addition, SF, but not adDAAO-derived  $H_2O_2$ , enhanced astrocytic intracellular GSH levels (Fig. S6B). Finally 7-h D-Ala pretreatment in adDAAO astrocytes before neuronal plating with HCA failed to preserve GSH levels in the cocultures (Fig. S6C).

**Microarray Analysis of Astrocytic Low-Level DAAO-induced  $H_2O_2$  Generation.** As other prosurvival transcription factors, such as NF- $\kappa$ B, are also redox-regulated, we performed an unbiased analysis of the transcriptional changes induced by low-level  $H_2O_2$  (induced by 0.016 mM D-Ala) in adDAAO astrocytes using two microarray approaches: (i) high density genome-wide and (ii) custom-designed microarray platform. The genome-wide approach showed no significant transcriptional changes, including no changes in a battery of Nrf2-regulated genes, in response to low-level  $H_2O_2$  generation (Figs. S6D and S7). However, the more sensitive custom-designed microarray approach uncovered several significant changes induced by low-level  $H_2O_2$ , most notably the up-regulation of interleukin 1- $\beta$  (*IL-1 $\beta$* ) and caveolin 1 (*CAV1*), and the down-regulation of transglutaminase 2, an enzyme whose selective inhibition has been associated with neuroprotection (23) (Table S1). The  $H_2O_2$ -induced regulated genes were almost entirely independent from genes controlled by the Nrf2-activator SF, such as *GFAP* (Tables S2 and S3). Together, these microarray data further support the lack of involvement of Nrf2 in mediating the  $H_2O_2$  effect and provide insight into potential low level  $H_2O_2$ -dependent mechanisms.

**PTP Inhibition Mimicks the Neuroprotective Effect of Astrocytic  $H_2O_2$ .** PTPs are uniquely and highly sensitive to oxidation-induced inactivation by physiological  $H_2O_2$  levels because of the low  $pK_a$  of cysteine residues found within their catalytic domain (2). Indeed,

PTP inhibition can enhance interleukin levels (24), and IL-1 $\beta$  was up-regulated in our gene-array analysis (Table S1). Thus, to establish if low-level H<sub>2</sub>O<sub>2</sub>-induced PTP inactivation is a plausible mechanism responsible for the astrocyte-dependent neuroprotective effect, astrocytes were pretreated with three structurally diverse PTP inhibitors before neuronal plating. Indeed, sodium orthovanadate, phenylarsine oxide, and BVT-948 mimicked the astrocytic H<sub>2</sub>O<sub>2</sub>-induced neuroprotection (Fig. 6 A–C and Fig S8 A–C). Consistent with the H<sub>2</sub>O<sub>2</sub>-induced neuroprotection, BVT-948 (which inhibits PTPs via H<sub>2</sub>O<sub>2</sub> generation) was most effective at the lowest concentration tested.

## Discussion

Herein we provide evidence that regulatable, continuous, low-level astrocytic H<sub>2</sub>O<sub>2</sub> production for 7 h mediates the protection of adjacent neurons from oxidative stress (Figs. 3B and 4 B and C). Although previous studies employing bolus H<sub>2</sub>O<sub>2</sub> have provided important insights (4, 6, 7), bolus application does not emulate localized and continuous cellular H<sub>2</sub>O<sub>2</sub> production. The rgDAAO method overcomes many of the potential confounds introduced by bolus addition of H<sub>2</sub>O<sub>2</sub> and allows easy control of the level and duration of intracellular H<sub>2</sub>O<sub>2</sub> production not offered by other enzymatic models (Fig. 1D). Our ability to manipulate astrocytic H<sub>2</sub>O<sub>2</sub> production demonstrates how H<sub>2</sub>O<sub>2</sub> can act as a protective messenger or a lethal toxin for adjacent neurons, depending on the concentration generated (Figs. 3B and 4 B and C). Of note, H<sub>2</sub>O<sub>2</sub>'s neurotoxic effects are attributable to diffusion into the extracellular space (Fig. 3E), but H<sub>2</sub>O<sub>2</sub>'s protective functions reflect its local role in astrocytes (Fig. 4E). We used several independent strategies to show that H<sub>2</sub>O<sub>2</sub> does not activate Nrf2 to mediate its salutary, astrocyte-dependent effects (Fig. 5 and Fig. S6).

Central to Nrf2 regulation is the repressor protein Keap1 (12). Debate surrounds the exact mechanism by which Nrf2 evades Keap1-dependent proteasomal degradation and the precise cellular signals that prompt Nrf2 activation. Keap1 is a cysteine-rich protein containing 25 to 27 cysteine residues (15). The cysteine thiol group is nucleophilic, providing an ideal target for electrophiles that readily accept electron pairs. Electrophiles, such as SF, menadione, 15d-PGJ2, isoliquiritigenin, and tBHQ readily react with Keap1 cysteines and have thus been extensively characterized as potent Nrf2 activators (15, 25). Although H<sub>2</sub>O<sub>2</sub> possesses the capacity to oxidize cysteine residues, information on H<sub>2</sub>O<sub>2</sub>'s role in modulating the Keap1/Nrf2 system is not consistent. An attractive hypothesis is that H<sub>2</sub>O<sub>2</sub> accumulation beyond a homeostatic threshold is the intracellular signal initiating Nrf2-dependent gene transcription and providing feedback regulation to limit oxidative damage. Indeed, the treatment of numerous cell types (including astrocytes) with H<sub>2</sub>O<sub>2</sub> leads to Nrf2 activation (17, 18, 26, 27). However, the levels of exogenous H<sub>2</sub>O<sub>2</sub> required to induce Nrf2 activation (mid micromolar to low millimolar) are unlikely to be produced by most cells. In fact, H<sub>2</sub>O<sub>2</sub> only transiently oxidizes


Keap1 (28) and is unable to overcome the inhibitory effect of Keap1 overexpression on Nrf2 activation (25). Not surprisingly, others have found no effect of H<sub>2</sub>O<sub>2</sub> on Nrf2 in astrocytes and keratinocytes (16, 19). Thus, our data showing that enzymatic low level H<sub>2</sub>O<sub>2</sub> production in astrocytes protects neurons independent of Nrf2 activation is in-line with numerous reports showing minimal to no effect of H<sub>2</sub>O<sub>2</sub> on the Nrf2/Keap1 system.

Accumulating evidence points to a protective role of ROS, such as H<sub>2</sub>O<sub>2</sub>, in the CNS. ROS/H<sub>2</sub>O<sub>2</sub> are necessary for neuroprotective preconditioning in in vitro models of ischemia and oxidative stress (29–31). In brain slices subjected to hypoxia, H<sub>2</sub>O<sub>2</sub> spares neurons from irreversible firing inhibition and induces neuroprotection (32, 33). In retinal cells, H<sub>2</sub>O<sub>2</sub>-initiated AKT signaling is necessary to prevent apoptosis (34). Our current results expand the established protective effect of H<sub>2</sub>O<sub>2</sub> to show that enzymatic H<sub>2</sub>O<sub>2</sub> production in one cell-type (astrocytes) affords protection to a neighboring cell population (neurons).

In the CNS and other tissues, cells respond to hypoxic or oxidative stress by initiating endogenous protective cascades often regulated at the transcriptional level. Thus, we used two microarray approaches (high-density genome-wide and custom-designed) to explore potential transcriptional changes initiated by low-level H<sub>2</sub>O<sub>2</sub>. Both microarray analyses support the lack of Nrf2 involvement (Fig. S6D and Tables S1, S2, and S3). In addition, the more sensitive custom-designed microarray uncovered transcriptional changes in response to low-level H<sub>2</sub>O<sub>2</sub>, providing potential mechanistic insight into the astrocyte-dependent neuroprotective pathway. Two of the most up-regulated genes were *IL-1 $\beta$*  and *CAVI* (Table S1). Although interleukins are normally associated with inflammation-induced neurotoxicity, IL-6 was recently found to mediate astrocyte-dependent neuroprotection (35). Caveolins are components of lipid rafts and play a large role in facilitating cell signaling by compartmentalizing proteins involved in signal transduction (36), thus representing an attractive candidate protein in mediating the astrocyte-dependent neuroprotective effect.

Other plausible mechanisms include the H<sub>2</sub>O<sub>2</sub>-induced posttranslational modification of proteins, such as PTPs, which are avidly and reversibly oxidized by low-level H<sub>2</sub>O<sub>2</sub> (2). Indeed, the inhibition of PTPs specifically in astrocytes induced potent and durable neuroprotection (Fig. 6 A–C), mimicking the H<sub>2</sub>O<sub>2</sub> effect. In fact, PTP inhibition has been shown to be neuroprotective in spinal cord injury (37), suggesting that PTPs are potential candidates in mediating H<sub>2</sub>O<sub>2</sub>'s astrocytic neuroprotective effect. PTP inhibition-mediated astrocytic neuroprotection was not restricted to a 7-h time-window, as seen with low-level H<sub>2</sub>O<sub>2</sub>. This finding suggests that low-level H<sub>2</sub>O<sub>2</sub> generation for 7 h induces the favorable reversible oxidative modification of target proteins (i.e., sulfenic acidification of PTPs), but diminished protection by 24 h indicates a possible switch to the irreversible sulfonic and sulfonic acidification of proteins by H<sub>2</sub>O<sub>2</sub>, which may hamper the neuroprotective effect. Future studies will address this question. Regardless of a transcriptional or posttranslational mechanism, our findings that 7-h low-level H<sub>2</sub>O<sub>2</sub> production in astrocytes is neuroprotective challenges the current dogma that pre- or postconditioning is a biphasic response that involves a short-lived (2–4 h) posttranscriptional change in proteins and a longer-lived (24–72 h) transcriptional change involving the expression of hundreds of adaptive genes (38).

In closing, our data demonstrate that astrocytic H<sub>2</sub>O<sub>2</sub> contributes to neurosurvival or death, depending on the levels generated, adding to a growing body of literature showing that astrocyte-specific mechanisms influence neuronal fate (13, 14). Prior studies have revealed a salutary, Nrf2-mediated role for astrocytes in overcoming neuronal death in Parkinson disease and ALS (13, 14). Our studies confirm the importance of Nrf2 in the CNS but point to unexpected, unique astrocytic mechanisms that work independently of Nrf2. The important role of low-level astrocytic H<sub>2</sub>O<sub>2</sub> in protecting neurons from oxidative stress underscores the complexity of redox biology and provides insight into the beneficial role of astrocyte-derived oxidants in the CNS.



**Fig. 6.** PTP inhibition in astrocytes induces the neuroprotection of adjacent neurons. Astrocytes were treated at the indicated time points (data are grouped by hour of astrocyte pretreatment) with (A) BVT-948, (B) phenylarsine oxide (PAO), or (C) sodium orthovanadate (Na OV). Following wash-off, neurons were plated + 5 mM HCA for 48 h and neuronal viability quantified. Values are the averages of four to five experiments  $\pm$  SEM. \*,  $P \leq 0.05$ , PTP inhibitor vs. HCA Ctl. Data in the absence of HCA are shown in Fig. S8.

## Materials and Methods

More detailed descriptions of the methods and materials used can be found in *SI Materials and Methods*.

**Cell Culture.** Primary astrocyte cultures were prepared from the cerebral cortices of rat pups (P1–3). Primary neuronal cultures were prepared from the forebrains of rat embryos (E17). Dissociation was performed as described by Ratan et al. (22).

**Adenoviral Transduction.** Cultured astrocytes were treated with the adenoviral vectors at a multiplicity of infection of 15 for 4 h in serum-free medium.

**Extracellular H<sub>2</sub>O<sub>2</sub> Measurement.** A HRP/Amplex Red substrate system was used to monitor extracellular H<sub>2</sub>O<sub>2</sub> levels in live astrocytes.

**Immunocytochemistry.** Cells were paraformaldehyde-fixed and incubated with primary/secondary antibodies and mounted with a DAPI-containing solution.

**GSH Measurements.** Intracellular total GSH was determined using the GSH-Glo(TM) Glutathione Assay kit (Promega).

**Neuronal Viability.** Fixed cocultures were incubated with antibodies for the neuronal specific marker MAP2 followed by HRP-conjugated secondary antibodies. HRP activity was then monitored using an Amplex Red reaction buffer.

**Astrocyte Viability.** Astrocyte viability was quantified using the CellTiter 96 Assay (Promega).

**Live-Cell Imaging.** Phase contrast images were taken with a Nikon Eclipse TS 100.

**Western Blots.** Following SDS/PAGE, transfer to nitrocellulose membrane and primary/secondary antibody incubation, astrocyte protein bands were detected with an infrared imaging system (LI-COR Biosciences).

**ARE-Luciferase Reporter Assay.** Astrocytes were transduced with adenoviral vectors containing the ARE sequence upstream of a luciferase reporter. Luciferase activity was measured using a luciferase assay kit (Promega).

**Small Interfering RNA Transfections.** Nrf2 knock down was achieved using siRNA targeted against Nrf2. Cultured astrocytes were transfected with the siRNAs plus the transfection reagent *TransIT-siQUEST* (Mirus) overnight.

**Quantitative PCR.** Total RNA was isolated from primary rat astrocytes using the NucleoSpin RNA II kit. A TaqMan RNA-to-CR<sub>1</sub>R 1-Step Kit was used for real-time PCR.

**Statistical Analysis.** Unless otherwise stated, statistical significance was determined by a one-way ANOVA followed by posthoc Newman Keuls or Dunnett's test using Statistica software (StatSoft). To determine the significance of the rate of H<sub>2</sub>O<sub>2</sub> production, a main-effects ANOVA was performed.

**ACKNOWLEDGMENTS.** We thank Dr. Brian Ross and Dr. Alnawaz Rehemtulla (rgDAAO vector), Dr. Jeffrey Johnson (ARE-Luc vectors), and Dr. Larry Oberly (catalase vector); the Whitehead Genome Technology Core and Casey Perley for help with microarray analysis; Melissa D'Annibale and Kathryn McLaughlin for preparing neurons for initial experiments; Vicki Brandt for her editorial help; and Dr. Alexander Mongin for helpful technical and conceptual comments. Support was provided by National Institutes of Health Grants NS04059 and NS39170 (to R.R.R.) and AG17617 and MH086385 (to S.D.G.); Center of Research Excellence in Spinal Cord Injury Grant CO19772 (to R.R.R.); and Hartman Foundation (to R.R.R.).

- Janssen-Heininger YM, et al. (2008) Redox-based regulation of signal transduction: Principles, pitfalls, and promises. *Free Radic Biol Med* 45:1–17.
- Rhee SG (2006) Cell signaling. H<sub>2</sub>O<sub>2</sub>, a necessary evil for cell signaling. *Science* 312:1882–1883.
- Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T (1995) Requirement for generation of H<sub>2</sub>O<sub>2</sub> for platelet-derived growth factor signal transduction. *Science* 270:296–299.
- Essers MA, et al. (2004) FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. *EMBO J* 23:4802–4812.
- Schreck R, Rieber P, Baeuerle PA (1991) Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF- $\kappa$ B transcription factor and HIV-1. *EMBO J* 10:2247–2258.
- Yin Y, et al. (1998) Involvement of p85 in p53-dependent apoptotic response to oxidative stress. *Nature* 391:707–710.
- Ahn SH, et al. (2005) Sterile 20 kinase phosphorylates histone H2B at serine 10 during hydrogen peroxide-induced apoptosis in *S. cerevisiae*. *Cell* 120:25–36.
- Terman JR, Mao T, Pasterkamp RJ, Yu HH, Kolodkin AL (2002) MICALs, a family of conserved flavoprotein oxidoreductases, function in plexin-mediated axonal repulsion. *Cell* 109:887–900.
- Bao L, et al. (2009) Mitochondria are the source of hydrogen peroxide for dynamic brain-cell signaling. *J Neurosci* 29:9002–9010.
- Andersen JK (2004) Oxidative stress in neurodegeneration: Cause or consequence? *Nat Med* 10(Suppl):S18–S25(7).
- Shih AY, et al. (2003) Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. *J Neurosci* 23:3394–3406.
- Kaspar JW, Niture SK, Jaiswal AK (2009) Nrf2:INrf2 (Keap1) signaling in oxidative stress. *Free Radic Biol Med* 47:1304–1309.
- Vargas MR, Johnson DA, Sirkis DW, Messing A, Johnson JA (2008) Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. *J Neurosci* 28:13574–13581.
- Chen PC, et al. (2009) Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. *Proc Natl Acad Sci USA* 106:2933–2938.
- Eggle AL, Liu G, Pezzuto JM, van Breemen RB, Mesecar AD (2005) Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2. *Proc Natl Acad Sci USA* 102:10070–10075.
- Lee JM, Calkins MJ, Chan K, Kan YW, Johnson JA (2003) Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. *J Biol Chem* 278:12029–12038.
- Piccirillo S, Filomeni G, Brüne B, Rotilio G, Ciriolo MR (2009) Redox mechanisms involved in the selective activation of Nrf2-mediated resistance versus p53-dependent apoptosis in adenocarcinoma cells. *J Biol Chem* 284:27721–27733.
- Shih AY, Erb H, Murphy TH (2007) Dopamine activates Nrf2-regulated neuroprotective pathways in astrocytes and meningeal cells. *J Neurochem* 101:109–119.
- Durchdewald M, et al. (2007) Electrophilic chemicals but not UV irradiation or reactive oxygen species activate Nrf2 in keratinocytes in vitro and in vivo. *J Invest Dermatol* 127:646–653.
- Pollegioni L, et al. (2002) Yeast D-amino acid oxidase: Structural basis of its catalytic properties. *J Mol Biol* 324:535–546.
- Stegman LD, et al. (1998) Induction of cytoxic oxidative stress by D-alanine in brain tumor cells expressing *Rhodotorula gracilis* D-amino acid oxidase: A cancer gene therapy strategy. *Hum Gene Ther* 9:185–193.
- Ratan RR, Murphy TH, Baraban JM (1994) Oxidative stress induces apoptosis in embryonic cortical neurons. *J Neurochem* 62:376–379.
- McConoughey SJ, et al. (2010) Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. *EMBO Mol Med* 2:349–370.
- Zhou D, Collins CA, Wu P, Brown EJ (2010) Protein tyrosine phosphatase SHP-1 positively regulates TLR-induced IL-12p40 production in macrophages through inhibition of phosphatidylinositol 3-kinase. *J Leukoc Biol* 87:845–855.
- Kobayashi M, et al. (2009) The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds. *Mol Cell Biol* 29:493–502.
- Chowdhury I, et al. (2009) Oxidant stress stimulates expression of the human peroxiredoxin 6 gene by a transcriptional mechanism involving an antioxidant response element. *Free Radic Biol Med* 46:146–153.
- Jain AK, Jaiswal AK (2007) GSK-3 $\beta$  acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2. *J Biol Chem* 282:16502–16510.
- Fourquet S, Guerois R, Biard D, Toledano MB (2010) Activation of NRF2 by nitrosative agents and H<sub>2</sub>O<sub>2</sub> involves KEAP1 disulfide formation. *J Biol Chem* 285:8463–8471.
- McLaughlin B, et al. (2003) Caspase 3 activation is essential for neuroprotection in preconditioning. *Proc Natl Acad Sci USA* 100:715–720.
- Chang S, Jiang X, Zhao C, Lee C, Ferriero DM (2008) Exogenous low dose hydrogen peroxide increases hypoxia-inducible factor-1 $\alpha$  protein expression and induces preconditioning protection against ischemia in primary cortical neurons. *Neurosci Lett* 441:134–138.
- Furuichi T, Liu W, Shi H, Miyake M, Liu KJ (2005) Generation of hydrogen peroxide during brief oxygen-glucose deprivation induces preconditioning neuronal protection in primary cultured neurons. *J Neurosci Res* 79:816–824.
- Geracitano R, et al. (2005) Protective role of hydrogen peroxide in oxygen-deprived dopaminergic neurons of the rat substantia nigra. *J Physiol* 568:97–110.
- Nisticò R, et al. (2008) Neuroprotective effect of hydrogen peroxide on an in vitro model of brain ischaemia. *Br J Pharmacol* 153:1022–1029.
- Mackey AM, et al. (2008) Redox survival signalling in retina-derived 661W cells. *Cell Death Differ* 15:1291–1303.
- Fujita T, Tozaki-Saitoh H, Inoue K (2009) P2Y1 receptor signaling enhances neuroprotection by astrocytes against oxidative stress via IL-6 release in hippocampal cultures. *Glia* 57:244–257.
- Stern CM, Mermelstein PG (2010) Caveolin regulation of neuronal intracellular signaling. *Cell Mol Life Sci*, 10.1007/s00018-010-0447-y.
- Nakashima S, et al. (2008) Small-molecule protein tyrosine phosphatase inhibition as a neuroprotective treatment after spinal cord injury in adult rats. *J Neurosci* 28:7293–7303.
- Dirnagl U, Becker K, Meisel A (2009) Preconditioning and tolerance against cerebral ischaemia: From experimental strategies to clinical use. *Lancet Neurol* 8:398–412.